EICHORCondition: Melanoma · Sponsor: Amgen
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * At least 18 years of age * Completely removed melanoma by surgery performed within 12 weeks of randomization * Advanced Melanoma * Tumor tissue from the resected site of the disease must be available for biomarker analyses in order to be randomized * Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Exclusion Criteria: * Previous anti-cancer treatment * Known hypersensitivity to monoclonal antibodies or to any of the excipients of the study drug * Ocular or uveal melanoma or history of carcinomatosis meningitis * History of auto-immune disease * Subject has medical conditions requiring systemic immunosuppression with either corticosteroids or other immunosuppressive medications within 14 days of the first dose of the investigational product Other protocol-defined inclusion/exclusion criteria apply
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Cancer and Blood Specialty clinic | Long Beach, California, United States | — |
| St. Vincent Frontier Cancer Center - Oncology | Billings, Montana, United States | — |
| Centro De Investigaciones Medicas Mar Del Plata (CIMMDP) - Rheumatology | Mar Del Plata, Río Negro Province, Argentina | — |
| Clinical Center University of Sarajevo - Clinic of Oncology | Sarajevo, Kanton Sarajevo, Bosnia and Herzegovina | — |
| University Clinical Centre of the Republic of Srpska - Gastroenterology | Banja Luka, Republika Srpska, Bosnia and Herzegovina | — |
| University Clinical Center Tuzla - Oncology, Hematology and Radio | Tuzla, Tuzlanski Kanton, Bosnia and Herzegovina | — |
| Cantonal hospital Zenica - Oncology | Zenica, Zeničko-dobojski Kanton, Bosnia and Herzegovina | — |
| University Clinical Hospital Mostar - Clinic for Lung Diseases | Mostar, Bosnia and Herzegovina | — |
| ATO Oncologia | Fortaleza, Ceará, Brazil | — |
| Hospital Sao Rafael | Salvador, Estado de Bahia, Brazil | — |
| Hospital Sirio Libanes - Brasilia - Oncology | Brasília, Federal District, Brazil | — |
| Instituto de Oncologia do Parana | Curitiba, Paraná, Brazil | — |
+ 64 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05907122